Asthma And COPD Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

Asthma is chronic respiratory disease that causes inflammation of narrowing of airways. COPD (Chronic Obstructive Pulmonary Disease) is a lung disease that makes breathing difficult including chronic bronchitis and emphysema and that gets worse with time. COPD is one of the leading cause of mortality and morbidity worldwide, with prevalence rate of 5-13%. Prevalence rate is directly proportional to increase in smoking rates and air population, especially in developing countries. Both for asthma and COPD, new pharmacologic options have being explored, by focusing on specific biological mechanisms knowing the pathogenesis of these diseases. Thus, with entrant of novel drugs may offer better treatment options. Though the generic entry of drug might affect the market, slowing the growth of the market. With key players innovating novel combination therapies, use of biologics, personalization treatment would drive the asthma and COPD drugs market.

The report titled “Asthma and COPD Drugs Market - Growth, Future Prospects and Competitive Analysis, 2021-2029” offers strategic insights into the overall asthma and COPD drugs market along with the market size and estimates for the duration 2019 to 2029. The said research study covers in-depth analysis of multiple market segments based on type of drugs and different geographies. The drug types studied for analyzing the overall global asthma and COPD drugs market are majorly segmented into anti-inflammatory drugs, bronchodilator monotherapy and combination drugs. Anti-inflammatory drugs includes corticosteroids, anti-leukotrienes and monoclonal antibodies. Bronchodilator monotherapy includes short-acting beta2-agonist (SABAs) and long-acting beta2-agonist (LABAs) and anticholinergics.

Geographically, the global asthma and COPD drugs market is studied for the following regional markets:

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• Rest of Europe
• Asia-Pacific
• China
• Japan
• Rest of Asia Pacific
• Latin America
• Mexico
• Brazil
• Rest of LATAM
• Middle East and Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2019-2029. Market growth rates for the forecast period 2021-2029 are also included in this report, considering 2020 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global asthma and COPD drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global asthma and COPD drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global asthma and COPD drugs market. In-depth competitive environment analysis and historical (2019) market size data are also provided in the report.

Based on the type of drugs, the global asthma and COPD market is segmented as follows:

• Anti-inflammatory drugs
• Corticosteroids
• Anti-Leukotrienes
• Monoclonal antibodies
• Bronchodilator monotherapy
• Short-acting beta2-agonist (SABAs)
• Long-acting beta2-agonist (LABAs)
• Anticholinergics
• Combination drugs

Currently treatment available for asthma and COPD includes anti-inflammatory drugs bronchodilator monotherapy and combination therapy, among which combination therapy dominates the market. The most favoured combination preferred for treatment are long-acting beta2 agonist (LABA)/ inhaled corticosteroid (ICS) combination that include Symbicort (AstraZeneca), Advair (GlaxoSmithKline). The combination most preferred due to better efficacy and convenient delivery mechanism, and decreased side effects. Singulair, Seretide and Spiriva are commonly used medication for treatment of asthma and COPD in the US and Europe. Further, with increase in use of corticosteroids in combination with bronchodilators would drive the treatment market of asthma and COPD. Recent treatments such as combination products once-a-daily and monoclonal antibodies will create new growth opportunity for the market. There are many undergoing studies at various stage of development in pipeline. Pharmaceutical companies have being investing heavily in research and development of new biologics with help of biotechnology which would create immense market opportunities for sustainable development of the asthma and COPD market. Novartis' immunoglobulin E (IgE) inhibitor Xolair (omalizumab) is the only biologics available in the market currently for treatment of asthma. Benralizumab Astrazenca’s first biologics is expected to enter the market next year that would create new wave for use of biologics for treatment of asthma.

For the purpose of this study, the global asthma and COPD market is geographically categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

At present, North America dominates the global asthma and COPD market followed by the European market. The major drivers for the North American market are rising prevalence of asthma and COPD, technological advancements in treatment, delay in the influx of generics, and strong pipeline of novel therapies. Prevalence of asthma and COPD is increasing in developed countries due to smoking, sedentary lifestyle, obesity, genetic factors, etc. Rise in the demand of the treatment and high cost of treatment also contribute to market growth. Asia-Pacific is anticipated to be the fastest growing market during the forecast period. In emerging countries such as China, India, and others there is increase in the incidences of asthma and other respiratory diseases due to rise in pollution, urbanization, sedentary lifestyle, and prolonged life expectancy.


This product will be delivered within 2 business days.